PROC (Procaps Group) Net Profit

Corporate emblem and logo of procapsgroup.com (PROC)

Procaps Group S.A. (PROC) is a Latin American pharmaceutical holding company with a broad product portfolio that mitigates local risks through global exports. However, currency volatility and asset integration challenges are creating certain pressures. The company's profit trend demonstrates current financial resilience, with the value stabilizing at 0.00. Stability is supported by high plant utilization and the scheduled upgrading of automated control systems.

PROC (Procaps) Company Net Income history from 07/04/2022 to 02/16/2025

Financial and market metric breakdowns for Procaps (PROC)

- price and consensus price forecast:
Stock Quotes Procaps Group Corp|PROC - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Procaps Group Corp|PROC - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Procaps|PROC - Company Book Value|Market-to-Book Ratio procapsgroup.com|PROC - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Procaps Group S.A.|PROC - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Procaps Group|PROC - Company Aggregate Debts|Debts to Book Value Procaps Group Corp|PROC - Company Long-Term Debt|Company Short-Term Loans and Borrowings Procaps|Critical Liquidity Ratio procapsgroup.com
- net income and valuation multiples indicators:
PROC - Company Net Income
Fundamental valuation:PROC Procaps Group Corp
Flagship merchandise of Procaps Group

Assessing asset reliability begins with analyzing the actual capital growth for each trading day, which prevents overpaying at peaks of marginality. This metric measures net income, reflecting the effectiveness of implementing ESG standards in the capsule production of Procaps Group S.A. (PROC), and therefore the company's stable profit trend confirms the balance between environmental responsibility and the financial sustainability of the business.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|SCPH - Company Net Income|Final Profit TECX (Tectonic Therapeutic, Inc.)|Tonix Pharmaceuticals (TNXP) - Company Net Income|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Net Income BioHarvest Sciences, Inc. (BHST)|Net Profit EXOZ|Net Profit oramed.com (ORMP)|Company Net Income Entera Bio ENTX|HYFT (ipatherapeutics.com) - Profit After Tax|ABVC - Company Net Income|Net Financial Result Cumberland Pharmaceuticals Inc CPIX|QNTM (Quantum BioPharma Limited) - Net Income|FibroGen Corporation - Final Profit|TELO (Telomir Pharmaceuticals) - Net Profit|RANI - Annual Net Income|Company Net Income Synergy CHC Corp (SNYR)|RLYB (rallybio.com) - Final Profit|Company Net Income Lexaria Bioscience Corp. LEXX|Pulmatrix Corporation (PULM) - Company Net Income|PTHL: Net Income|APM - Net Profit|Lyra Therapeutics (LYRA) - Company Net Income|Profit After Tax IBO (impactbiomedinc.com)|Net Income TNFA|YCBD: Final Profit|Company Net Income PainReform Ltd. (PRFX)|Net Financial Result altamiratherapeutics.com|Lipella Pharmaceuticals, Inc. - Net Income|Net Financial Result OptiNose Inc (OPTN)|Pieris - Net Profit|PTPI - Net Profit|QLI (Qilian International) - Net Income|SLRN - Net Financial Result|Company Net Income TFF Pharmaceuticals, Inc.